Patents by Inventor Hans Hofland
Hans Hofland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10251885Abstract: The present invention relates generally to antifugal compositions. In an embodiment, the antifungal compositions are effective for application to nails and surrounding skin, and comprise at least one volatile solvent, at least one film forming substance, and at least one pyrimidone derivative of formula I, such as albaconazole. These compositions are capable of treating an infection caused by fungi, such as onychomychosis.Type: GrantFiled: May 27, 2010Date of Patent: April 9, 2019Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITEDInventors: Jon Lenn, Hans Hofland, Edward Hsia
-
Publication number: 20180360791Abstract: The present invention relates to a method of treating a fungal condition caused by T. rubrum, by administering a composition comprising a fatty acid monoester of glycerol. According to an embodiment, the fatty acid monoester of glycerol is 1-monocaprin.Type: ApplicationFiled: February 22, 2018Publication date: December 20, 2018Inventors: Jon D. LENN, Hans Hofland, Barry Thomas Hunt, Edward Hsia
-
Patent number: 10092736Abstract: A device for dispensing a topically administered drug has a spreader which is used to actuate a pump to release the drug and then to spread the drug on the skin and. The spreader is coupled to a lock that prevents it from actuating the pump after a number of drug doses have been dispensed. The pump can be actuated to release no more than the selected quantity of drug per day or actuation.Type: GrantFiled: May 4, 2016Date of Patent: October 9, 2018Assignee: Demira, Inc.Inventors: Hans Hofland, Delphine Caroline Imbert, Daniel O'Connell, Allen Pearson
-
Patent number: 9440056Abstract: A device for dispensing a topically administered drug has a spreader which is used to actuate a pump to release the drug and then to spread the drug on the skin and. The spreader is coupled to a lock that prevents it from actuating the pump after a number of drug doses have been dispensed. The pump can be actuated to release no more than the selected quantity of drug per day or actuation.Type: GrantFiled: September 29, 2015Date of Patent: September 13, 2016Assignee: Demira, Inc.Inventors: Hans Hofland, Delphine Caroline Imbert, Daniel O'Connell, Allen Pearson
-
Publication number: 20160243345Abstract: A device for dispensing a topically administered drug has a spreader which is used to actuate a pump to release the drug and then to spread the drug on the skin and. The spreader is coupled to a lock that prevents it from actuating the pump after a number of drug doses have been dispensed. The pump can be actuated to release no more than the selected quantity of drug per day or actuation.Type: ApplicationFiled: May 4, 2016Publication date: August 25, 2016Inventors: Hans Hofland, Delphine Caroline Imbert, Daniel O'Connell, Allen Pearson
-
Publication number: 20160089526Abstract: A device for dispensing a topically administered drug has a spreader which is used to actuate a pump to release the drug and then to spread the drug on the skin and. The spreader is coupled to a lock that prevents it from actuating the pump after a number of drug doses have been dispensed. The pump can be actuated to release no more than the selected quantity of drug per day or actuation.Type: ApplicationFiled: September 29, 2015Publication date: March 31, 2016Inventors: Hans Hofland, Delphine Caroline Imbert, Daniel O'Connell, Allen Pearson
-
Patent number: 9062037Abstract: The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.Type: GrantFiled: August 20, 2014Date of Patent: June 23, 2015Assignee: Stiefel Laboratories, Inc.Inventors: Xue Ge, Hansen Wong, Wendy Huang Chern, Hans Hofland, Michael J. Bishop, Xin Frank Cai, Alan Colborn
-
Publication number: 20140357669Abstract: The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.Type: ApplicationFiled: August 20, 2014Publication date: December 4, 2014Inventors: Xue GE, Hansen WONG, Wendy Huang CHERN, Hans HOFLAND, Michael J. BISHOP, Xin Frank CAI, Alan COLBORN
-
Publication number: 20140357672Abstract: The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.Type: ApplicationFiled: August 20, 2014Publication date: December 4, 2014Inventors: Xue GE, Hansen WONG, Wendy Huang CHERN, Hans HOFLAND, Michael J. BISHOP, Xin Frank CAI, Alan COLBORN
-
Publication number: 20140249143Abstract: Provided are certain compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections.Type: ApplicationFiled: October 19, 2012Publication date: September 4, 2014Applicant: GlaxoSmithKline LLCInventors: Anna Lindsey Banka, Janos Botyanszki, Eric Gregory Burroughs, John George Catalano, Wendy Huang Chern, Hamilton D. Dickson, Margaret J. Gartland, Robert Hamatake, Hans Hofland, Jesse Daniel Keicher, Christopher Brooks Moore, John Bradford Shotwell, Matthew David Tallant, Jean-Philippe Therrien, Shihyun You
-
Publication number: 20120128612Abstract: The present invention relates generally to antifugal compositions. In an embodiment, the antifungal compositions are effective for application to nails and surrounding skin, and comprise at least one volatile solvent, at least one film forming substance, and at least one pyrimidone derivative of formula I, such as albaconazole. These compositions are capable of treating an infection caused by fungi, such as onychomychosis.Type: ApplicationFiled: May 27, 2010Publication date: May 24, 2012Applicant: PALAU PHARMA, S.A.Inventors: Jon Lenn, Hans Hofland, Edward Hsia
-
Publication number: 20120115909Abstract: The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.Type: ApplicationFiled: July 16, 2010Publication date: May 10, 2012Inventors: Xue Ge, Hansen Wong, Wendy Huang Chern, Hans Hofland, Michael J. Bishop, Xin Frank Cai, Alan Colborn
-
Publication number: 20110305646Abstract: The present invention relates to a method of treating a fungal condition caused by T. rubrum, by administering a composition comprising a fatty acid monoester of glycerol. According to an embodiment, the fatty acid monoester of glycerol is 1-monocaprin. According to another embodiment, the fungal condition is onychomycosis.Type: ApplicationFiled: March 19, 2010Publication date: December 15, 2011Inventors: Jon Lenn, Hans Hofland, Barry Hunt, Edward Hsia
-
Publication number: 20060069055Abstract: The present invention concerns methods and formulations for non-parental delivery of nucleic acid molecules to cells. In particular, the present invention relates to methods and formulations that enhance the transport of poly- and oligonucleotides across biological membranes.Type: ApplicationFiled: September 21, 2005Publication date: March 30, 2006Inventors: Maya Dajee, Rolf Ehrhardt, Hans Hofland, Leslie Mcevoy, Tony Muchamuel, Brian Schryver
-
Publication number: 20050095281Abstract: The present invention provides liposomal formulations comprising a lipid vesicle and at least one single chain lipid active agent. In addition, the present invention provides methods for using the same for preventing an infection in a mammal.Type: ApplicationFiled: March 12, 2004Publication date: May 5, 2005Applicants: OPTIME Therapeutics, Inc., Megee-Womens Health CorporationInventors: Hans Hofland, Lisa Rohan
-
Publication number: 20040224010Abstract: The present invention provides, inter alia, novel, liposome-based formulations for enhanced ophthalmic drug delivery. Such ophthalmic drug formulations are useful for treating ocular inflammation stemming from, for example, iritis, conjunctivitis, seasonal allergic conjunctivitis, acute and chronic endophthalmitis, anterior uveitis, uveitis associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, masquerade syndromes including ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy, corneal abrasion, or blood-aqueous barrier disruption, and for treating post-operative ocular inflammation, resulting from, for example, photorefractive keratectomy, cataract removal surgery, intraocular lens implantation or radial keratotomy.Type: ApplicationFiled: November 13, 2003Publication date: November 11, 2004Applicant: OPTIME Therapeutics, Inc.Inventors: Hans Hofland, Juiiet Bongianni, Tobias Wheeler
-
Publication number: 20020146829Abstract: Processes for making neutral or anionic complexes containing sequestered DNA for gene transfer, by forming a stable colloid containing an aqueous phase having suspended therein a first DNA complex with a cationic surface potential comprising a DNA sequence complexed with a cationic lipid or polymer, and modifying the surface potential of the first DNA complex to form a stable colloid comprising a second DNA complex with a neutral or net anionic surface potential.Type: ApplicationFiled: November 29, 2001Publication date: October 10, 2002Applicant: Aventis Pharmaceuticals Products Inc.Inventors: Hans Hofland, Donald Lamons, Xiao-Ying Meng
-
Publication number: 20020022264Abstract: Stable polynucleotide delivery vehicles (SPDVs) are described which incorporate a polynucleotide/cationic lipid complex as structural components of the SPDV. The subject SPDVs may optionally incorporate synthetic biodegradable amphipathic lipids, and suitable targeting agents.Type: ApplicationFiled: March 16, 2001Publication date: February 21, 2002Inventors: Sean M. Sullivan, Hans Hofland
-
Publication number: 20010044147Abstract: Stable polynucleotide delivery vehicles (SPDVs) are described which incorporate a polynucleotide/cationic lipid complex as structural components of the SPDV. The subject SPDVs may optionally incorporate synthetic biodegradable amphipathic lipids, and suitable targeting agents.Type: ApplicationFiled: May 16, 2001Publication date: November 22, 2001Inventors: Sean M. Sullivan, Hans Hofland